Histocompatibility Antigens Class I
"Histocompatibility Antigens Class I" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Membrane glycoproteins consisting of an alpha subunit and a BETA 2-MICROGLOBULIN beta subunit. In humans, highly polymorphic genes on CHROMOSOME 6 encode the alpha subunits of class I antigens and play an important role in determining the serological specificity of the surface antigen. Class I antigens are found on most nucleated cells and are generally detected by their reactivity with alloantisera. These antigens are recognized during GRAFT REJECTION and restrict cell-mediated lysis of virus-infected cells.
| Descriptor ID |
D015395
|
| MeSH Number(s) |
D12.776.395.550.489 D12.776.543.550.439 D23.050.301.500.100 D23.050.705.552.100
|
| Concept/Terms |
Histocompatibility Antigens Class I- Histocompatibility Antigens Class I
- Class I Histocompatibility Antigens
- Class I Antigens
- Antigens, Class I
- I Antigens, Class
- Class I Major Histocompatibility Antigens
|
Below are MeSH descriptors whose meaning is more general than "Histocompatibility Antigens Class I".
Below are MeSH descriptors whose meaning is more specific than "Histocompatibility Antigens Class I".
This graph shows the total number of publications written about "Histocompatibility Antigens Class I" by people in this website by year, and whether "Histocompatibility Antigens Class I" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1996 | 1 | 0 | 1 |
| 1997 | 1 | 0 | 1 |
| 1998 | 2 | 2 | 4 |
| 1999 | 0 | 1 | 1 |
| 2000 | 2 | 0 | 2 |
| 2001 | 1 | 0 | 1 |
| 2002 | 2 | 0 | 2 |
| 2003 | 2 | 1 | 3 |
| 2004 | 2 | 3 | 5 |
| 2005 | 3 | 2 | 5 |
| 2006 | 0 | 2 | 2 |
| 2007 | 2 | 0 | 2 |
| 2008 | 2 | 1 | 3 |
| 2009 | 1 | 2 | 3 |
| 2011 | 2 | 0 | 2 |
| 2012 | 0 | 3 | 3 |
| 2013 | 3 | 4 | 7 |
| 2014 | 1 | 3 | 4 |
| 2015 | 2 | 0 | 2 |
| 2017 | 2 | 0 | 2 |
| 2018 | 5 | 0 | 5 |
| 2019 | 3 | 2 | 5 |
| 2020 | 2 | 0 | 2 |
| 2021 | 1 | 1 | 2 |
| 2022 | 0 | 2 | 2 |
| 2023 | 1 | 1 | 2 |
| 2024 | 1 | 2 | 3 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Histocompatibility Antigens Class I" by people in Profiles.
-
MICBG406A polymorphism reduces risk of mechanical ventilation and death during viral acute lung injury. JCI Insight. 2025 Aug 08; 10(15).
-
Immunopeptidomic MHC-I profiling and immunogenicity testing identifies Tcj2 as a new Chagas disease mRNA vaccine candidate. PLoS Pathog. 2024 Dec; 20(12):e1012764.
-
Longitudinal analysis of the gut microbiota during anti-PD-1 therapy reveals stable microbial features of response in melanoma patients. Cell Host Microbe. 2024 Nov 13; 32(11):2004-2018.e9.
-
Perioperative chemoimmunotherapy induces strong immune responses and long-term survival in patients with HLA class I-deficient non-small cell lung cancer. J Immunother Cancer. 2024 Oct 20; 12(10).
-
Distinct Non-Human Leukocyte Antigen Antibody Signatures Correlate with Endothelial Crossmatch Status in Lung and Renal Transplant Recipients. Int J Mol Sci. 2024 Sep 30; 25(19).
-
Astrocyte-induced Cdk5 expedites breast cancer brain metastasis by suppressing MHC-I expression to evade immune recognition. Nat Cell Biol. 2024 10; 26(10):1773-1789.
-
Neoantigen-specific cytotoxic Tr1 CD4 T cells suppress cancer immunotherapy. Nature. 2024 Aug; 632(8023):182-191.
-
Assessment of human leukocyte antigen-based neoantigen presentation to determine pan-cancer response to immunotherapy. Nat Commun. 2024 Feb 08; 15(1):1199.
-
Current perspectives on mass spectrometry-based immunopeptidomics: the computational angle to tumor antigen discovery. J Immunother Cancer. 2023 10; 11(10).
-
The pattern of MHC class I expression in muscle biopsies from patients with myositis and other neuromuscular disorders. Rheumatology (Oxford). 2023 09 01; 62(9):3156-3160.